Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Oncologists who Treat RCC (EU)(?)

Council Members in this Study Group: 22

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Rossana Berardi, MD
Consultant Medical Oncologist
UniversitĂ  Politecnica delle Marche

Rossana Berardi, MD, is a Researcher and Lecturer - Consultant Medical Oncologist in the Department of Medical Oncology at the Universita Politecnica delle Marche, Italy, since November 2005. She is involved in clinical research and GCP trials on the treatment of solid tumors in particular on gastrointestinal...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Lenalidomide is recently proving that its potential is not limited to myeloma, but can be used also in other B-cell malignancy settings such as lymphoma and CLL. CLL, in particular, needs light and yet efficacious treatments, particularly in the setting of pretreated (at times heavily) patients.

Biological efficacy has been shown for a number of cancer vaccines. Clinical efficacy has been shown in few of them. Clinical benefit just in one: idiotype vaccine for B-cell lymphoma. TroVax still has to clear the last hurdle, and likely also the second one.

The use of immunoconjugates in the development of monoclonal antibodies has been long tested with toxins but not with pro-drugs

Early detection of ovarian cancer is of paramount importance

All major clinical trials in  patients with pancreatic cancer have generated questionable actual benefit

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Academic Institution*
  • Government/Military Hospital or Clinic
  • Lab, Academic Medical Center
  • Non-Academic Community Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Consultancy, Healthcare-Focused
  • Facility, Academic Medical Center

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Director
  • Physician - Director
  • Professor
  • Physician - Department Chair
  • Research Scientist
  • Consultant
  • Medical Director
  • Owner

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880